RTX (RTX) investor relations material

Executive summary

• Revenue and profitability grew strongly in the first nine months, led by the Enterprise and Healthcare segments, with Enterprise stabilizing and Healthcare showing strong momentum.

• Guidance was raised and narrowed for the full year, reflecting improved visibility and confidence, despite currency headwinds and short order cycles limiting forecast visibility.

• The Enterprise segment, especially retail, drove performance, while Healthcare advanced on product sales and integration into system sales.

• Strategic focus remains on expanding the global customer base and reinforcing long-term growth.

Financial highlights

• Q3 revenue reached DKK 146.9m, up 3.5% YoY; 9M revenue rose 16.7% YoY to DKK 407.3m, with gross margin improving to 51.7% in Q3 and 50.7% for 9M.

• EBITDA for 9M was DKK 22.2m, a turnaround from -20.1m last year; EBIT for 9M was DKK 2.5m (vs. -50.6m YoY); net profit for 9M was DKK 5.9m (vs. -40.1m YoY).

• Free cash flow for 9M was DKK 18.5m, compared to -14.2m last year; net liquidity at period end was DKK 118.9m, above policy range.

• Inventory reduced to DKK 56.5m (from DKK 90.7m YoY), mainly due to lower component inventory, with further reductions expected.

• Gross margin consistently above 50% for the year, driven by favorable product mix and Healthcare growth.

Outlook and guidance

• Full-year 2024/25 guidance: revenue DKK 530–560m, EBITDA DKK 25–35m, EBIT DKK -5 to 5m; gross margin expected to exceed last year.

• Growth anticipated in Enterprise and Healthcare segments, with orderbook building but visibility limited to 3–6 months.

• Capacity costs expected to rise slightly due to salary inflation and strategic hires.

• Inventory reduction expected to continue as component sourcing normalizes.

• ProAudio segment anticipated to return to growth and improved profitability as the business model shifts to modules.